Mateus Kaba Aboud

Cooley advised Jocasta Neuroscience, a preclinical-stage, longevity-focused company, on its $35 million Series A financing. Its lead asset, a proprietary formulation of the longevity protein a - Klotho, is used to treat a range of conditions, including cognitive impairment in neurodegenerative diseases.

Cooley advised Ambiq Micro, a technology leader in ultra-low-power semiconductor solutions for edge artificial intelligence, on its $96 million initial public offering (IPO).

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine and patient care through artificial intelligence, on its offering of $650 million aggregate principal amount of 0.75% convertible senior notes due 2030 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Cooley advised Tempus AI (Nasdaq: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its agreement to acquire Ambry Genetics, a company focusing on genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Cooley advised PetIQ (Nasdaq: PETQ), a leading pet medication, health and wellness company, on its definitive merger agreement with Bansk Group, pursuant to which Bansk Group will acquire all outstanding shares of PetIQ’s common stock for $31 per share in an all-cash transaction valued at approximately $1.5 billion.